Publications
Biselele T., Bambi J., Betukumesu D. M., Ndiyo Y., Tabu G., Kapinga J., Bola V, Makaya P., Tjabbes H., Vis P., Peeters-Scholte C.. A Phase IIa Clinical Trial of 2 ‑ Iminobiotin for the Treatment of Birth Asphyxia in DR Congo , a Low ‑ Income Country. Pediatr. Drugs. 22(1). 2020 [Link to publication].
Kogame A., Ishikawa K., DeJongh J., Tagawa Y., Matsui H., Moriya Y., Kondo T., Asahi S. Pharmacokinetic and pharmacodynamic modeling of the metastin/kisspeptin analog, TAK-448, for its anti-tumor efficacy in a rat xenograft model. Biopharm. Drug Dispos.: 2020. [Link to publication]
Hoefman S., Snelder N., van Noort M., Garcia-Hernandez A., Onkels H., Larsson T.E., Bergmann K.R. Mechanism-based modeling of the effect of a novel inhibitor of vascular adhesion protein-1 on albuminuria and renal function markers in patients with diabetic kidney disease. J Pharmacokinet Pharmacodyn. 2020 [Link to publication]
Snelder N., Hoefman S., Garcia-Hernandez A., Onkels H., Larsson T.E., Bergmann K.R. Population pharmacokinetics and pharmacodynamics of a novel vascular adhesion protein-1 inhibitor using a multiple-target mediated drug disposition model. J Pharmacokinet Pharmacodyn. 2020 [Link to publication]
Keunecke A., Hoefman S., Drenth H.J., Zisowsky J., Cleton A., Ploeger B.A. Population pharmacokinetics of regorafenib in solid tumours: Exposure in clinical practice considering enterohepatic circulation and food intake. Br. J. Clin. Pharmacol.(December 2019): 1–15, 2020 [Link to publication]
Favie L. M. A., Peeters-Scholte C. M. P. C. D., Bakker A., Tjabbes H., Egberts T. C. G., van Bel F., Rademaker C. M. A., Vis P., Groenendaal F. Pharmacokinetics and short-term safety of the selective NOS inhibitor 2-iminobiotin in asphyxiated neonates treated with therapeutic hypothermia. Pediatr. Res.: 2019. [Link to publication]
Fidler M., Wilkins J.J., Hooijmaijers R., Post T.M., Schoemaker R,. Trame M.N., Xiong Y., Wang W.. Nonlinear mixed-effects model development and simulation using nlmixr and related R open source packages. CPT Pharmacometrics Syst Pharmacol: 621-633, 2019. [Link to publication]
Snelder N., Drenth H.J., Riber Bergmann K., Wood N.D., Hibberd M., Scott G. Population pharmacokinetic – pharmacodynamic modelling of the relationship between testosterone and prostate specific antigen in patients with prostate cancer during treatment with leuprorelin. Br J Clin Pharmacol: 1–13, 2019. [Link to publication]
Shah A., Solms A., Wiegmann S., Ahsman M., Berntorp E., Tiede A., Iorio A., Mancuso M.E., Zhivkov T., Lissitchkov T. Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A. Annals of Hematology: 2035-2044, 2019. [Link to publication]
Schoemaker R., Fidler M., Laveille C., Wilkins J. J., Hooijmaijers R., Post T. M., Trame M. N., Xiong Y., Wang W. Performance of the SAEM and FOCEI algorithms in the open-source non-linear mixed effect modelling tool nlmixr. CPT pharmacometrics Syst. Pharmacol.: 2019. [Link to publication]